Charles River Labs Cuts Animal Testing by 25% via Virtual Control Groups

Charles River Laboratories (NYSE: CRL) has published a landmark study validating the use of Virtual Control Groups (VCGs) to replace live animal controls in toxicology testing. The study demonstrated that VCGs can reduce animal usage by up to 25% while maintaining 100% concordance in No Observed Adverse Effect Level (NOAEL) assessments. This initiative, part of the company's AMAP program, aims to enhance ethical safety standards and operational efficiency through digital data integration. By adopting VCGs, the laboratory expects to achieve significant cost savings and faster study timelines for drug development. Furthermore, the move is anticipated to bolster the company’s ESG ratings, appealing to socially responsible investors. This technological advancement marks a critical shift in biopharmaceutical R&D, balancing scientific integrity with modern ethical requirements.